Longfei Liu1†
Qiao Xiao
Xiao Guan- 1Department of Urology, Xiangya Hospital, Central South University, Changsha, China
- 2Department of Radiology, Xiangya Hospital, Central South University, Changsha, China
- 3Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China
Apelin is an endogenous ligand that binds to the G protein-coupled receptor angiotensin-like-receptor 1 (APJ). Apelin and APJ are widely distributed in organs and tissues and are involved in multiple physiological and pathological processes including cardiovascular regulation, neuroendocrine stress response, energy metabolism, etc. Additionally, apelin/APJ axis was found to play an important role in cancer development and progression. Apela is a newly identified endogenous ligand for APJ. Several studies have revealed the potential role of Apela in cancers. In this article, we review the current studies focusing on the role of apelin/APJ signaling and Apela in different cancers. Potential mechanisms by which apelin/APJ and Apela mediate the regulation of cancer development and progression were also mentioned. The Apelin/APJ signaling and Apela may serve as potential therapeutic candidates for treatment of cancer.
Introduction
Apelin is a bioactive peptide isolated from bovine stomach in 1998 and is recognized as the endogenous ligand for angiotensin-like-receptor 1 (APJ), which belongs to the G protein coupled receptor family (1, 2). The apelin gene (APLN) in human is located on chromosome Xq25-q26.1. The APLN encodes a secreted precursor called preproapelin consisting of 77 amino acids. The preproapein is cleaved by endopetidases, generating several active forms of apelin including apelin-12, -13, -17, -36, and other (3–5). Among these forms, it has been discovered that apelin-13 and apelin-17 show stronger activity than apelin-36. The APJ gene is located on chromosome 11q12 and encodes a 380-amino acid protein. APJ is a G protein coupled receptor with 7 transmembrane domains which was first identified in 1993. It shows a close sequence homology to the angiotensin II receptor type 1 (6). However, APJ cannot bind Ang II. In human, the apelin/APJ axis is widely expressed in organs like heart, brain, kidney, placenta, etc. (7, 8). It has been demonstrated that the apelin/APJ system plays a pivotal role in multiple physiological processes including cardiovascular regulation, angiogenesis, pain, energy metabolism, fluid homeostasis, gastrointestinal function, neuroendocrine stress response and feeding behavior (4, 9–15).
Recently, a new endogenous peptide that binds to APJ was discovered. Apelin early ligand A (APELA), also known as Elabela, Toddler, and ELA, is an evolutionarily conserved peptide hormone that was firstly found to play a central role in zebrafish embryonic development by (16, 17). Apela gene is located on chromosome and encodes a 54-amino acid preprotein, which is converted into a mature secretory form of 32-amino acid peptide after removal of the 22-residue signal peptide (17). The presence of cysteine residue in Apela following loss of signal peptide is an important feature that distinguish Apela and apelin (18) {Shin, 2017 #88; Pauli, 2014 #72; Shin, 2017 #88}. In zebrafish, it has been revealed that during development the Apela is expressed during gastrulation at the same time as APJ, whereas apelin is not expressed until the end of gastrulation (17). The spatiotemporal expression pattern of Aplea and APJ and receptor internalization experiments both indicate the possibility of Apela functioning as a ligand of APJ. Moreover, loss of Apela gene leaded to a phenotype similar to APJ gene deficiency, but different from APLN gene (19, 20). It has been demonstrated that Apela could activate APJ in vitro and apelin binding to APJ could rescue Apela deficiency (16, 17). It is considered that Apela/APJ signaling might be responsible for various physiological and pathological processes including blood pressure regulation, cardiac contractility, angiogenesis, fluid homeostasis, anti-renal fibrosis. Results suggest that Apela/APJ axis could guide angioblast to migrate to the midline to control vascular patterning in zebrafish embryos (21). Besides, losses of Apela could lead to preeclampsia and cardiovascular malformations (22).
Growing evidence has revealed the potential role of apelin/APJ system and Apela in various tumors in recent years (23, 24). It has been demonstrated that apelin expression is significantly increased in human non-small cell lung cancer (NSCLC) (25). The apelin expression correlated with poor overall survival (OS) and apelin could stimulate tumor growth and microvessel densities in vivo in NSCLC. Apelin gene upregulation was detected in half of the skin tumor samples (26). In postmenopausal breast cancer (BC) patients, high levels of apelin was observed (27). In several ovarian cancer subtypes, expression of Apela was elevated (28). These results indicate that apelin/APJ axis may play a critical role in the initiation and development of oncologic diseases. Hence, apelin/APJ axis and Apela can be considered as a therapeutic target in treating cancers. In this review, we would summarize the newest progression on the role of apelin/APJ system as well as Apela signaling in different cancers.
Role of APELIN/APJ on Various Cancers
Gastric and Gastroesophageal Cancer
For patients with advanced gastric cancer (GC), concurrent chemoradiotherapy (CRT) is the standard treatment (29, 30). However, response of this treatment is still low. Endostar is a modified recombinant human endostatin which could inhibit vascular endothelial growth factor (VEGF) expression in human GC cell line (31). However, effective marker of treatment response prediction is still lacking for GC patients receiving combination therapy of CRT and endostar. Hao et al. found that patients with high APJ expression had significant poorer response rate to combined therapy than patients with low APJ expression in the CRT plus endostar group (32). Patients with high APJ expression had significant low overall OS compared with those with low APJ expression. Hence, APJ can be used to predict treatment response in GC patients receiving combined therapy of CRT and endostar. In a study by Feng et al., it was revealed that tumor apelin levels, rather than serum apelin levels, correlated with advanced tumor stage, poor tumor differentiation, lymph node metastases and distant metastases. Compared with patients with low apelin levels and those with weak or negative apelin staining, patients with high tumor apelin levels showed a significantly shorter OS (33). The two studies indicated the important role of apelin/APJ axis in GC. Recently, Guan et al. discovered that circ-NOTCH1 could upregulate the expression of APLN by inhibiting the transcriptional activity of miR-637, leading to the regulation of cell growth in GC cell lines (34). This finding provided more evidence about the role of apelin in GC.
Contrary to the findings by Feng et al., in patients with gastroesophageal cancer (GEC), tumor apelin level as well as serum apelin level were increased compared with normal controls (35). Serum apelin levels positively correlated with high sensitive C-reactive protein (hsCRP) levels, indicating the potential role of apelin in systemic inflammatory response in GEC. These results suggested that apelin/APJ signaling may play a role in the progression of GC and GEC.
Lung Cancer
It has been shown that compared with normal lung tissue, there was a significant increase in apelin mRNA levels in human NSCLC samples (25). High apelin protein levels correlated with elevated microvessel densities and poor OS, revealing the role of apelin in angiogenesis and clinical outcome of NSCLC. Yang et al. found that apelin-13 could promote lung adenocarcinoma cell proliferation and induced cell autophagy via extracellular signal–regulated kinases (ERK) 1/2 signaling (36). Ran et al. discovered that apelin could promote lung cancer A549 cells proliferation and invasion by inhibiting exosomal miR-15a-5p (37). Interestingly, a recent study revealed that miR-195 could directly target apelin, thus inhibiting lung adenocarcinoma cell proliferation and invasion (38). Lv et al. revealed that apelin-13 promoted lung adenocarcinoma cells migration by phosphorylating p21-activated kinase (PAK) 1 and cofilin, suggesting that apelin/APJ and downstream signaling may be potential therapeutic targets for anti-metastasis in patients with lung adenocarcinoma (39).
Recently, it was found that levels of serum apelin-12 were significantly higher in non-patient smokers than healthy non-smokers. Considering the subtype of lung cancers, the levels of serum apelin-12 were highest in patients with squamous cell carcinoma (SCC) compared to those with adenocarcinoma, small cell carcinoma and other malignancies (40). This result indicated that elevated levels of serum apelin-12 may contribute to the outbreak of lung SCC in non-patient smokers.
It has been proved that apelin plays an important role in angiogenesis in lung cancer. Uribesalgo et al. found that inhibition of apelin could lead to the modulating of tumor microenvironment, inhibition of tumor angiogenesis and tumor growth decreasing (41). By blocking apelin, it could prevent resistance and metastasis that induced by anti-angiogenic therapy. Prediction of clinical outcomes of patients with NSCLC treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) still remains difficult. Efforts are under way to develop potential biomarkers. Yang et al. found that compared with expression levels of apelin in the EGFR-TKIs sensitive group, there was a significant increase in the apelin expression in the EGFR-TKIs resistant group (42). High apelin expression may contribute to EGFR-TKIs resistance through modulating angiogenesis. The above studies indicated that apelin/APJ may contribute to lung cancer development and progression. Expression and role of apelin/APJ signaling in GC, GEC and lung cancer are summarized in Table 1.
Table 1 Expression and role of apelin/APJ signaling in gastric cancer, gastroesophageal cancer and lung cancer.
Colon Cancer
Picault et al. revealed that apelin was overexpressed in human colon adenomas and adenocarcinomas (43). Overexpression of APJ was also observed in surrounding tissues. The proliferation rate of colorectal cancer cell lines was significantly reduced by treating them with apelin-13 receptor antagonist. These findings showed us the potential of apelin/APJ signaling as therapeutic target for colon cancer treatment. Similarly, Liu et al. discovered that elevated apelin expression was found in colon tumor compared with adjacent non-tumor tissue in the same patient (44).
Chen et al. found that apelin-13 could stimulate Notch3 expression in colorectal cancer cell line LS180. LS180 proliferation was inhibited by blocking either APJ or Notch3, suggesting that apelin-13/APJ could promote colorectal cancer cell proliferation by modulating Notch3 pathways (45). In a study by Podgórska et al., four apelin peptides, including [Pyr1] apelin-13, apelin-13, apelin-17, and apelin-36, could promote colon cancer cells migration and invasion (46).
As an anti-angiogenesis monoclonal antibody, bevacizumab has been used in several cancers. However, only 10% to 15% of patients with colorectal cancer could benefit from bevacizumab therapy (47). Thus, biomarkers that can predict treatment response of bevacizumab in colorectal cancer patients are of urgent need. Zuurbier et al. found that expression of apelin mRNA was significantly higher in bevacizumab non-response group compared to bevacizumab response group (47). Besides, overexpression of apelin protein was associated with poor progression-free survival in patients receiving bevacizumab treatment. Thus, apelin may be used as a novel biomarker in predicting bevacizumab response in patients with colorectal cancer. These results showed us the ability of apelin/APJ signaling in colon cancer development. Expression and role of apelin/APJ signaling in colon cancer are summarized in Table 2.
Table 2 Expression and role of apelin/APJ signaling in colon cancer.
Brain Tumor
Glioma is most common malignant tumor in the brain with a poor prognosis. Treatment for glioma still remains difficult. In a study by Kälin et al., expression of apelin and APJ was elevated in microvascular proliferations of malignant gliomas (48). Zhang et al. revealed that circular RNA circ-ZNF264 can upregulate miR-4493 target gene apelin expression, leading to glioma cell proliferation, invasion and inhibition of apoptosis (49).
Glioblastoma is a highly aggressive brain tumor with an extremely poor prognosis. Glioblastoma stem-like cells (GSCs), a subpopulation of tumor-initiating cells, have played a critical role in tumor initiation, tumor invasion, angiogenesis and treatment resistance (50–52). GSCs reside closely to vascular beds, into which endothelial cells secrete unknown factors that can regulate their plasticity, survival and fate (53, 54). Wright et al. found that endothelial cells could produce apelin (53, 54). In vitro, apelin could increase GSC expansion (53). Both in vitro and in vivo, inhibition of APJ could lead to a significant reduction in tumor growth (53). The study by Frisch et al. showed a similar result (55). Knockdown of APLN resulted in reduction of tumor vasculature in glioblastoma (55). The results of these studies undercover the potential of apelin/APJ signaling as a drug target for glioblastoma. Mastrella et al. discovered that compared to controls, knockdown or knockout of APLN in orthotopic models of proneural or classical glioblastoma subtypes contributed to a significant reduction in glioblastoma vascularization (56). However, apelin expression reduction was found to promote glioblastoma cell invasion. These results indicated the dichotomous roles of apelin/APJ signaling in tumor invasion and angiogenesis in glioblastoma. Besides, the authors also discovered that apelin-F13A could bind to APJ, leading to the inhibition of glioblastoma cell invasion and tumor angiogenesis. All these results revealed that apelin/APJ axis may play an important role in brain tumor.
Hepatocellular Carcinoma
Cancer-associated fibroblast (CAF) plays an important role in promoting cancer cells invasion. CAF could cause up-regulation of some genes in hepatocellular carcinoma (HCC) cells (57). However, it still requires investigation on how HCC cells could affect CAF gene expression. It was found that human HCC cell line HCC38/KMUH could upregulate APLN in CAF cell line F26/KMUH. Muto et al. demonstrated that apelin/APJ axis was overexpressed in HCC and could regulate angiogenesis in HCC (58). In another study, apelin was found to have the potential to transform epithelial cells and initiate HCC progression in hepatitis-C virus (HCV) chronic hepatitis (59).
Cabiati et al. revealed that expression of apelin/APJ axis was significantly elevated in liver recipients compared with liver donors from liver specimens obtained from HCV-positive HCC who underwent liver transplantation (60). Lee et al. discovered that high APJ expression correlated with presence of microvascular invasion, intrahepatic metastasis and early recurrence in HCC (61). Multivariate analysis revealed that high APJ expression independently predicted a shorter recurrence-free survival in HCC. In a recent study focusing on role of apelin in HCC, the findings showed that by binding to APJ, apelin could activate phosphatidylinositol 3-kinase (PI3K)/Akt pathway, resulting in an increase in expression of phospho-glycogen synthase kinase 3β (p-GSK3β) and cyclin D1 (62). ML221, an APJ antagonist, could inhibit Apelin-PI3K/Akt signaling pathway and HCC growth both in vitro and in vivo. In a study by Huang et al., it demonstrated that apelin-13 may induce autophagy in HCC cell line HepG2 cells by activating ERK1/2 and upregulating Beclin1 expression (63). Apelin/APJ may play critical roles in HCC development. Expression and role of apelin/APJ signaling in brain tumor and HCC are summarized in Table 3.
Table 3 Expression and role of apelin/APJ signaling in brain tumor and HCC.
Genitourinary Cancers and Pelvic Cancers
Apelin/APj axis was also found to play an important role in genitourinary cancers. Zhang et al. found that apelin mRNA expression was up-regulated in clear cell renal cell carcinoma (ccRCC) specimens from the GSE6344 microarray dataset (64). However, there was no significant difference between ccRCC tissue and adjacent normal tissues in apelin mRNA expression obtained from their center (64). Levels of plasma apelin were elevated in patients with hyponatremia, which correlated with a greater risk of cancer progression and death (65). Tolkach et al. found that APJ mRNA expression was significantly associated with tumor aggressiveness in ccRCC. APJ expression was negatively associated with programmed cell death-ligand 1 (PD-L1) expression in ccRCC cells in a subset ccRCC of patients (66). In muscle-invasive bladder cancer, apelin protein expression level was elevated in tumor tissues compared with adjacent normal tissues (67). High expression of apelin significantly correlated with high tumor stage, distant metastasis, vascular invasion and may have the potential to indicate poor prognosis. In prostate cancer (PCa), Wan et al. found that microRNA miR-224 could target apelin gene. In PCa tissues, down-regulation of miR-224 was negatively associated with the up-regulation of apelin mRNA (68). Furthermore, upregulation of apelin was more discovered in PCa with advanced stage, metastasis and prostate-specific antigen failure. It was also revealed that apelin-13 could promote human PCa cells LNCaP proliferation through an androgen receptor-dependent manner (69).
In a study by Altinkaya et al., serum levels of apelin were higher in patients with endometrial cancer than controls (70). Apelin levels were significantly associated with body mass index (BMI). High apelin levels were found to be associated with an increased risk of endometrial cancer. Dupont et al. discovered that adipokines, including apelin, may activate different signaling pathways like PI3K/Akt, AMP-activated protein kinase (AMPK), and peroxisome proliferator-activated receptor (PPAR) that might contribute to the development of ovarian cancer (71). In ovarian cancer, APJ expression levels were higher in epithelial cancer cells than in granulosa tumor cells and apelin could act as a mitogenic factor in ovarian cancer cell line OVCAR-3 cell, promoting its proliferation and growth (72). In another study, it was revealed that compared to controls, APJ overexpressed tumors showed reduced response to sorafenib treatment in xenograft model in ovarian cancer (73). In genitourinary cancers and pelvic cancers, the apelin/APJ signaling may have important impact.
Other Types of Cancers
In patients with multiple myeloma, levels of plasma apelin were significantly elevated compared with those in non-Hodgkin lymphoma and healthy controls (74). Patients with high apelin level had a better prognosis. Heo et al. demonstrated that expression of apelin was significantly associated with tumor recurrence and disease-free survival in oral squamous cell carcinoma (OSCC) (75). Under hypoxic conditions, apelin expression was upregulated and exogenous apelin could stimulated the proliferation and migration of oral cancer cell line HSC-3 through phosphorylation of ERK1/2. The results suggest the potential of hypoxia-induced apelin as a new therapeutic target for OSCC. Apelin/APJ expression was also significantly increased in pancreatic adenocarcinoma (26, 73). In cholangiocarcinoma, expression of the apelin/APJ was increased. In vitro, apelin could promote human cholangiocarcinoma cells Mz-ChA-1 proliferation and angiogenesis which could be inhibited by ML221. Growth of xenograft mice was inhibited by ML221 treatment (76). In postmenopausal patients with breast cancer, an increase in level of serum apelin-36 was detected and was positively associated with BMI (27). These results indicated that apelin and APJ may play important roles in different types of cancers. Expression and role of apelin/APJ signaling in genitourinary cancers, pelvic cancers and other types of cancer are summarized in Table 4.
Table 4 Expression and role of apelin/APJ signaling in genitourinary cancers, pelvic cancers and other types of cancers.
Role of Apela in Cancers
Despite the various roles of Apela in biological functions, role of Apela in cancers is poorly understood. Recent years saw a significant increase in the studies focusing on the association between Apela and cancer. Soulet et al. found that Apela was usually expressed by epithelial cells while expression of APJ could be found in various kidney cells (77). Expression of Aplea was reduced in the main kidney cancer subtypes, namely, clear cell, papillary, and chromophobe RCC. In renal cancer cells, Apela could induced apoptosis and inhibited cell proliferation and migration through activating mTORC1 signaling. These results suggest the potential role of Apela in renal cell treatment. In another study by Artas et al., similar expression pattern of Apela was discovered. In chromophobe RCC, expression of Apela was significantly reduced compared to health controls while no expression of Apela was detected in papillary RCC or Fuhrman grade 1 and grade 2 ccRCC (78). However, there existed a significant increase in the expression of Apela in renal oncocytoma compared with health controls. Hence, Apela may be useful in differentiating benign and malign renal tumors.
In brain tumor patients, it was found that Apela mRNA and protein were both expressed at high levels in a subset of patients (79). High Apela expression correlated with poor survival in patients with glioma and glioblastoma and Apela expression was associated with glioma grade. However, gene expression of apelin or APJ was not found to be associated with patient survival or glioma grade. Artas et al. also discovered that there existed a significant difference in Apela expression between control tissues and glioma tissues (80). In high-grade glioma, expression of Apela was significantly higher than that in low-grade glioma.
In TMPRSS2-ERG subtype of locally advanced lymph node-positive PCa, Apela gene was identified to be associated with prognosis (81). In ovarian cancer, expression of Apela was elevated in various ovarian cancer subtypes, especially in ovarian clear cell carcinoma (OCCC) (28). APELA could promote OCCC cell line OVISE proliferation and migration in vitro. Furthermore, it was revealed that regulation of OCCC cell growth by Apela depended on p53 activity. These results uncovered different roles of Apela in different types of cancers including RCC, brain tumor and ovarian cancer. Expression and role of Apela in different types of cancers are summarized in Table 5.
Table 5 Expression and role of Apela signaling in different types of cancers.
Discussion
Expression of apelin/APJ signaling occurred in many cancers, suggesting a potential role of this axis in cancer development and progression. Apelin is involved in cancer cell proliferation in various cancers, including NSCLC, GC, oral squamous cell carcinoma, cholangiocarcinoma, PCa and ovarian cancer. It was revealed that apelin could promote cancer cell proliferation by increasing expression of factors involved in cell proliferation including cyclin D1, Ki-67, proliferating cell nuclear antigen (PCNA), and activating pathways like JAG1/Notch3, ERK1/2, and PI3K/Akt (73). Apelin could also increase cell migration in lung adenocarcinoma, GC and oral squamous cell carcinoma. There are several possible signaling pathways and factors involved in cell migration including PAK1/cofilin, mitogen-activated protein kinase (MAPK)/ERK, AMPK, PI3K/Akt, PPAR, bone morphogenetic protein (BMP)-2, focal adhesion kinase (FAK), matrix metalloproteinase (MMP), osteopontin (OPN), platelet derived growth factor (PDGF), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) and stromal cell-derived factor-1 alpha (SDF-1α)/CXC chemokine receptor-4 (CXCR4) (69, 73). The role of apelin/APJ signaling in contributing to angiogenesis is also well-recognized in various cancers (69, 73). Besides, the anti-apoptosis function of apelin is also well-described (82, 83). In several cancers, apelin could also protect cancer cells from apoptosis and increases cancer stability (43, 53). It has been revealed that apelin/APJ may also play a role in mediating differentiation of mesenchymal stem cells to cancer stem cells (73). Besides, apelin/APJ signaling may play a critical role in cancer stem cells self-renew by activating signaling pathways like wnt/β-catenin and Jagged/Notch (73). Furthermore,several studies have shown the pivotal role of apelin/APJ signaling in leading to resistance to anticancer drugs, especially chemotherapy and anti-angiogenic drugs (32, 39, 73). Figure 1 showed a simple overview of the apelin/APJ and Apela/APJ axis induced signaling pathways involved in cancer.
Figure 1 A simple overview of the apelin/APJ-induced signaling pathways and Apela/APJ-induced signaling pathways involved in cancer development and progression.
Compared to apelin, the role of Apela in cancer is not well studied. Researches are still under investigation. In renal cancer, Apela could induced apoptosis and inhibited cell proliferation and migration while Apela could promote ovarian clear cell carcinoma cell line proliferation and migration. The reason for the opposing roles of Apela in different cancers still remains unclear. Ovarian cancer cell line OVISE does not express APJ, suggesting that Apela may function in an APJ-independent pathway (28). Further investigations are needed.
The apelin, APJ and Apela are detected in many types of cancer. In most situations, expression levels of apelin, APJ and Aplea are elevated compared to health controls. Moreover, the apelin/APJ and Apela/APJ signaling contributed to cancer development and progression, indicating the potential of signaling as therapeutic targets for cancer treatment. However, the underlying mechanisms are still unclear. More studies should be carried out to get a better understanding of the function of apelin/APJ and Apela signaling in cancer.
Author Contributions
XG conceived and designed the idea, reviewed the manuscript. LL and XY wrote the manuscript. CL and YW completed the figure. QX, LZ, and YP prepared the tables. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by the National Natural Science Foundation of China (81902727).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. O’Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene (1993) 136(1-2):355–60. doi: 10.1016/0378-1119(93)90495-o
2. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun (1998) 251(2):471–6. doi: 10.1006/bbrc.1998.9489
3. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem (2000) 275(28):21061–7. doi: 10.1074/jbc.M908417199
4. Lv SY, Yang YJ, Chen Q. Regulation of feeding behavior, gastrointestinal function and fluid homeostasis by apelin. Peptides (2013) 44:87–92. doi: 10.1016/j.peptides.2013.03.024
5. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem (2000) 74(1):34–41. doi: 10.1046/j.1471-4159.2000.0740034.x
6. Antushevich H, Wojcik M. Review: Apelin in disease. Clin Chim Acta (2018) 483:241–8. doi: 10.1016/j.cca.2018.05.012
7. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther (2005) 107(2):198–211. doi: 10.1016/j.pharmthera.2005.04.001
8. Zhang J, Ren CX, Qi YF, Lou LX, Chen L, Zhang LK, et al. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci (2006) 79(12):1153–9. doi: 10.1016/j.lfs.2006.03.040
9. Wu D, He L, Chen L. Apelin/APJ system: a promising therapy target for hypertension. Mol Biol Rep (2014) 41(10):6691–703. doi: 10.1007/s11033-014-3552-4
10. Zhang L, Takara K, Yamakawa D, Kidoya H, Takakura N. Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy. Cancer Sci (2016) 107(1):36–44. doi: 10.1111/cas.12836
11. Bertrand C, Valet P, Castan-Laurell I. Apelin and energy metabolism. Front Physiol (2015) 6:115. doi: 10.3389/fphys.2015.00115
12. Newson MJ, Pope GR, Roberts EM, Lolait SJ, O’Carroll AM. Stress-dependent and gender-specific neuroregulatory roles of the apelin receptor in the hypothalamic-pituitary-adrenal axis response to acute stress. J Endocrinol (2013) 216(1):99–109. doi: 10.1530/JOE-12-0375
13. Lv SY, Yang YJ, Qin YJ, Mo JR, Wang NB, Wang YJ, et al. Central apelin-13 inhibits food intake via the CRF receptor in mice. Peptides (2012) 33(1):132–8. doi: 10.1016/j.peptides.2011.11.011
14. Lv SY, Qin YJ, Wang NB, Yang YJ, Chen Q. Supraspinal antinociceptive effect of apelin-13 in a mouse visceral pain model. Peptides (2012) 37(1):165–70. doi: 10.1016/j.peptides.2012.06.007
15. Lv S, Yang YJ, Hong S, Wang N, Qin Y, Li W, et al. Intrathecal apelin-13 produced different actions in formalin test and tail-flick test in mice. Protein Pept Lett (2013) 20(8):926–31. doi: 10.2174/0929866511320080010
16. Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell (2013) 27(6):672–80. doi: 10.1016/j.devcel.2013.11.002
17. Pauli A, Norris ML, Valen E, Chew GL, Gagnon JA, Zimmerman S, et al. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science (2014) 343(6172):1248636. doi: 10.1126/science.1248636
18. Shin K, Kenward C, Rainey JK. Apelinergic System Structure and Function. Compr Physiol (2017) 8(1):407–50. doi: 10.1002/cphy.c170028
19. Hamada J, Kimura J, Ishida J, Kohda T, Morishita S, Ichihara S, et al. Evaluation of novel cyclic analogues of apelin. Int J Mol Med (2008) 22(4):547–52. doi: 10.3892/ijmm_00000054
20. Zeng XX, Wilm TP, Sepich DS, Solnica-Krezel L. Apelin and its receptor control heart field formation during zebrafish gastrulation. Dev Cell (2007) 12(3):391–402. doi: 10.1016/j.devcel.2007.01.011
21. Helker CS, Schuermann A, Pollmann C, Chng SC, Kiefer F, Reversade B, et al. The hormonal peptide Elabela guides angioblasts to the midline during vasculogenesis. Elife (2015) 4. doi: 10.7554/eLife.06726
22. Ho L, van Dijk M, Chye STJ, Messerschmidt DM, Chng SC, Ong S, et al. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice. Science (2017) 357(6352):707–13. doi: 10.1126/science.aam6607
23. Yang Y, Lv SY, Ye W, Zhang L. Apelin/APJ system and cancer. Clin Chim Acta (2016) 457:112–6. doi: 10.1016/j.cca.2016.04.001
24. Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, et al. Identification of essential genes for cancer immunotherapy. Nature (2017) 548(7669):537–42. doi: 10.1038/nature23477
25. Berta J, Kenessey I, Dobos J, Tovari J, Klepetko W, Jan Ankersmit H, et al. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. J Thorac Oncol (2010) 5(8):1120–9. doi: 10.1097/JTO.0b013e3181e2c1ff
26. Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene (2007) 26(55):7692–9. doi: 10.1038/sj.onc.1210573
27. Salman T, Demir L, Varol U, Akyol M, Oflazoglu U, Yildiz Y, et al. Serum apelin levels and body composition changes in breast cancer patients treated with an aromatase inhibitor. J BUON (2016) 21(6):1419–24.
28. Yi Y, Tsai SH, Cheng JC, Wang EY, Anglesio MS, Cochrane DR, et al. APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecol Oncol (2017) 147(3):663–71. doi: 10.1016/j.ygyno.2017.10.016
29. Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol (2015) 33(28):3130–6. doi: 10.1200/JCO.2014.58.3930
30. Chung MJ, Kim H, Jung YS, Shin SK, Hyung WJ, Noh SH, et al. A pilot study for preoperative concurrent chemoradiotherapy with S-1 and cisplatin for locally advanced gastric cancer. Hepatogastroenterology (2013) 60(122):382–6.
31. Wang YB, Liu JH, Song ZM. Effects of recombinant human endostatin on the expression of vascular endothelial growth factor in human gastric cancer cell line MGC-803. BioMed Rep (2013) 1(1):77–9. doi: 10.3892/br.2012.3
32. Hao YZ, Li ML, Ning FL, Wang XW. APJ Is Associated with Treatment Response in Gastric Cancer Patients Receiving Concurrent Chemoradiotherapy and Endostar Therapy. Cancer Biother Radiopharm (2017) 32(4):133–8. doi: 10.1089/cbr.2016.2138
33. Feng M, Yao G, Yu H, Qing Y, Wang K. Tumor apelin, not serum apelin, is associated with the clinical features and prognosis of gastric cancer. BMC Cancer (2016) 16(1):794. doi: 10.1186/s12885-016-2815-y
34. Guan E, Xu X, Xue F. circ-NOTCH1 acts as a sponge of miR-637 and affects the expression of its target gene Apelin to regulate gastric cancer cell growth. Biochem Cell Biol (2020) 98(2):164–70. doi: 10.1139/bcb-2019-0079
35. Diakowska D, Markocka-Maczka K, Szelachowski P, Grabowski K. Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients. Dis Markers (2014) 2014:619649. doi: 10.1155/2014/619649
36. Yang L, Su T, Lv D, Xie F, Liu W, Cao J, et al. ERK1/2 mediates lung adenocarcinoma cell proliferation and autophagy induced by apelin-13. Acta Biochim Biophys Sin (Shanghai) (2014) 46(2):100–11. doi: 10.1093/abbs/gmt140
37. Ran JJ, Li Y, Liu L, Zhu Y, Ni Y, Huang H, et al. Apelin enhances biological functions in lung cancer A549 cells by downregulating exosomal miR-15a-5p. Carcinogenesis (2020) 42(2):243–53. doi: 10.1093/carcin/bgaa089
38. Zhou Y, Zhao M, Du Y, Liu Y, Zhao G, Ye L, et al. MicroRNA-195 suppresses the progression of lung adenocarcinoma by directly targeting apelin. Thorac Cancer (2019) 10(6):1419–30. doi: 10.1111/1759-7714.13087
39. Lv D, Li L, Lu Q, Li Y, Xie F, Li H, et al. PAK1-cofilin phosphorylation mediates human lung adenocarcinoma cells migration induced by apelin-13. Clin Exp Pharmacol Physiol (2016) 43(5):569–79. doi: 10.1111/1440-1681.12563
40. Gholamnejad M, Meghrazi K, Akhgar M, Shaianmehr M. The Assessment of Serum Apelin-12 Level in a Variety of Pulmonary Malignancies in Smokers. Addict Health (2019) 11(2):93–9. doi: 10.22122/ahj.v11i2.228
41. Uribesalgo I, Hoffmann D, Zhang Y, Kavirayani A, Lazovic J, Berta J, et al. Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy. EMBO Mol Med (2019) 11(8):e9266. doi: 10.15252/emmm.201809266
42. Yang S, Chen X, Pan Y, Yu J, Li X, Ma S. Proteins associated with EGFR-TKIs resistance in patients with non-small cell lung cancer revealed by mass spectrometry. Mol Med Rep (2016) 14(5):4823–9. doi: 10.3892/mmr.2016.5823
43. Picault FX, Chaves-Almagro C, Projetti F, Prats H, Masri B, Audigier Y. Tumour co-expression of apelin and its receptor is the basis of an autocrine loop involved in the growth of colon adenocarcinomas. Eur J Cancer (2014) 50(3):663–74. doi: 10.1016/j.ejca.2013.11.017
44. Liu Q, Hu T, He L, Huang X, Tian X, Zhang H, et al. Genetic targeting of sprouting angiogenesis using Apln-CreER. Nat Commun (2015) 6:6020. doi: 10.1038/ncomms7020
45. Chen T, Liu N, Xu GM, Liu TJ, Liu Y, Zhou Y, et al. Apelin13/APJ promotes proliferation of colon carcinoma by activating Notch3 signaling pathway. Oncotarget (2017) 8(60):101697–706. doi: 10.18632/oncotarget.21904
46. Podgorska M, Pietraszek-Gremplewicz K, Nowak D. Apelin Effects Migration and Invasion Abilities of Colon Cancer Cells. Cells (2018) 7(8). doi: 10.3390/cells7080113
47. Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, et al. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget (2017) 8(26):42949–61. doi: 10.18632/oncotarget.17306
48. Kalin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Brandli AW. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol (2007) 305(2):599–614. doi: 10.1016/j.ydbio.2007.03.004
49. Zhang F, Mai SR, Zhang L. Circ-ZNF264 Promotes the Growth of Glioma Cells by Upregulating the Expression of miR-4493 Target Gene Apelin. J Mol Neurosci (2019) 69(1):75–82. doi: 10.1007/s12031-019-01334-8
50. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev (2015) 29(12):1203–17. doi: 10.1101/gad.261982.115
51. Hale JS, Sinyuk M, Rich JN, Lathia JD. Decoding the cancer stem cell hypothesis in glioblastoma. CNS Oncol (2013) 2(4):319–30. doi: 10.2217/cns.13.23
52. Yan K, Yang K, Rich JN. The evolving landscape of glioblastoma stem cells. Curr Opin Neurol (2013) 26(6):701–7. doi: 10.1097/WCO.0000000000000032
53. Harford-Wright E, Andre-Gregoire G, Jacobs KA, Treps L, Le Gonidec S, Leclair HM, et al. Pharmacological targeting of apelin impairs glioblastoma growth. Brain (2017) 140(11):2939–54. doi: 10.1093/brain/awx253
54. Harford-Wright E, Gavard J. Apelin, the Devil Inside Brain Tumors. J Exp Neurosci (2018) 12:1179069518759680. doi: 10.1177/1179069518759680
55. Frisch A, Kalin S, Monk R, Radke J, Heppner FL, Kalin RE. Apelin Controls Angiogenesis-Dependent Glioblastoma Growth. Int J Mol Sci (2020) 21(11). doi: 10.3390/ijms21114179
56. Mastrella G, Hou M, Li M, Stoecklein VM, Zdouc N, Volmar MNM, et al. Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma. Cancer Res (2019) 79(9):2298–313. doi: 10.1158/0008-5472.CAN-18-0881
57. Lin ZY, Chuang WL. Hepatocellular carcinoma cells cause different responses in expressions of cancer-promoting genes in different cancer-associated fibroblasts. Kaohsiung J Med Sci (2013) 29(6):312–8. doi: 10.1016/j.kjms.2012.08.012
58. Muto J, Shirabe K, Yoshizumi T, Ikegami T, Aishima S, Ishigami K, et al. The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma. Anticancer Res (2014) 34(10):5313–20. doi: 10.1111/liv.12459
59. Farid RM, Abu-Zeid RM, El-Tawil A. Emerging role of adipokine apelin in hepatic remodelling and initiation of carcinogensis in chronic hepatitis C patients. Int J Clin Exp Pathol (2014) 7(5):2707–17.
60. Cabiati M, Gaggini M, De Simone P, Del Ry S. Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity. Clin Exp Med (2020). doi: 10.1007/s10238-020-00672-x
61. Lee T, Park CK, Ha SY. Prognostic Role of Apelin Receptor Expression in Hepatocellular Carcinoma Treated With Curative Surgical Resection. Anticancer Res (2019) 39(6):3025–31. doi: 10.21873/anticanres.13435
62. Chen H, Wong CC, Liu D, Go MYY, Wu B, Peng S, et al. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target. Theranostics (2019) 9(18):5246–60. doi: 10.7150/thno.34713
63. Huang Q, Liu X, Cao C, Lei J, Han D, Chen G, et al. Apelin-13 induces autophagy in hepatoma HepG2 cells through ERK1/2 signaling pathway-dependent upregulation of Beclin1. Oncol Lett (2016) 11(2):1051–6. doi: 10.3892/ol.2015.3991
64. Zhang HP, Zou J, Xu ZQ, Ruan J, Yang SD, Yin Y, et al. Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma. Oncol Lett (2017) 13(1):463–8. doi: 10.3892/ol.2016.5408
65. Lacquaniti A, Altavilla G, Picone A, Donato V, Chirico V, Mondello P, et al. Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation. Clin Exp Med (2015) 15(1):97–105. doi: 10.1007/s10238-014-0272-y
66. Tolkach Y, Ellinger J, Kremer A, Esser L, Muller SC, Stephan C, et al. Apelin and apelin receptor expression in renal cell carcinoma. Br J Cancer (2019) 120(6):633–9. doi: 10.1038/s41416-019-0396-7
67. Yang L, Li YL, Li XQ, Zhang Z. High Apelin Level Indicates a Poor Prognostic Factor in Muscle-Invasive Bladder Cancer. Dis Markers (2019) 2019:4586405. doi: 10.1155/2019/4586405
68. Wan Y, Zeng ZC, Xi M, Wan S, Hua W, Liu YL, et al. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer. Hum Pathol (2015) 46(2):295–303. doi: 10.1016/j.humpath.2014.10.027
69. Wysocka MB, Pietraszek-Gremplewicz K, Nowak D. The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer. Front Physiol (2018) 9:557. doi: 10.3389/fphys.2018.00557
70. Altinkaya SO, Nergiz S, Kucuk M, Yuksel H. Apelin levels are higher in obese patients with endometrial cancer. J Obstet Gynaecol Res (2015) 41(2):294–300. doi: 10.1111/jog.12503
71. Dupont J, Reverchon M, Cloix L, Froment P, Rame C. Involvement of adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian follicle development and cancer. Int J Dev Biol (2012) 56(10-12):959–67. doi: 10.1387/ijdb.120134jd
72. Hoffmann M, Fiedor E, Ptak A. Bisphenol A and its derivatives tetrabromobisphenol A and tetrachlorobisphenol A induce apelin expression and secretion in ovarian cancer cells through a peroxisome proliferator-activated receptor gamma-dependent mechanism. Toxicol Lett (2017) 269:15–22. doi: 10.1016/j.toxlet.2017.01.006
73. Masoumi J, Jafarzadeh A, Khorramdelazad H, Abbasloui M, Abdolalizadeh J, Jamali N. Role of Apelin/APJ axis in cancer development and progression. Adv Med Sci (2020) 65(1):202–13. doi: 10.1016/j.advms.2020.02.002
74. Maden M, Pamuk ON, Pamuk GE. High apelin levels could be used as a diagnostic marker in multiple myeloma: A comparative study. Cancer Biomark (2016) 17(4):391–6. doi: 10.3233/CBM-160654
75. Heo K, Kim YH, Sung HJ, Li HY, Yoo CW, Kim JY, et al. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol (2012) 48(6):500–6. doi: 10.1016/j.oraloncology.2011.12.015
76. Hall C, Ehrlich L, Venter J, O’Brien A, White T, Zhou T, et al. Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. Cancer Lett (2017) 386:179–88. doi: 10.1016/j.canlet.2016.11.025
77. Soulet F, Bodineau C, Hooks KB, Descarpentrie J, Alves I, Dubreuil M, et al. ELA/APELA precursor cleaved by furin displays tumor suppressor function in renal cell carcinoma through mTORC1 activation. JCI Insight (2020) 5(14). doi: 10.1172/jci.insight.129070
78. Artas G, Kuloglu T, Dagli AF, Ugur K, Yardim M, Aydin S, et al. A promising biomarker to distinguish benign and malignant renal tumors: ELABELA. Niger J Clin Pract (2019) 22(3):386–92. doi: 10.4103/njcp.njcp_105_18
79. Ganguly D, Cai C, Sims MM, Yang CH, Thomas M, Cheng J, et al. APELA Expression in Glioma, and Its Association with Patient Survival and Tumor Grade. Pharmaceuticals (Basel) (2019) 12(1). doi: 10.3390/ph12010045
80. Artas G, Ozturk S, Kuloglu T, Dagli AF, Gonen M, Artas H, et al. A Novel Candidate Molecule in the Pathological Grading of Gliomas: ELABELA. Turk Neurosurg (2018) 28(6):989–94. doi: 10.5137/1019-5149.JTN.22022-17.2
81. Kudryavtseva AV, Lukyanova EN, Kharitonov SL, Nyushko KM, Krasheninnikov AA, Pudova EA, et al. Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer. J Bioinform Comput Biol (2019) 17(1):1950003. doi: 10.1142/S0219720019500033
82. Chen L, Tao Y, Feng J, Jiang YR. Apelin Protects Primary Rat Retinal Pericytes from Chemical Hypoxia-Induced Apoptosis. J Ophthalmol (2015) 2015:186946. doi: 10.1155/2015/186946
Keywords: apelin, APJ, Apela, cancer, therapeutic targets
Citation: Liu L, Yi X, Lu C, Wang Y, Xiao Q, Zhang L, Pang Y and Guan X (2021) Study Progression of Apelin/APJ Signaling and Apela in Different Types of Cancer. Front. Oncol. 11:658253. doi: 10.3389/fonc.2021.658253
Received: 25 January 2021; Accepted: 17 March 2021;
Published: 12 April 2021.
Edited by:
Massimo Fantini, Precision Biologics, Inc., United StatesReviewed by:
Abdel-Majid Khatib, Institut National de la Santé et de la Recherche Médicale (INSERM), FranceJing Chen, University of Warwick, United Kingdom
Shuangyu Lv, Henan University, China
Copyright © 2021 Liu, Yi, Lu, Wang, Xiao, Zhang, Pang and Guan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiao Guan, 798477952@qq.com
†These authors have contributed equally to this work